口服二甲双胍的糖尿病患者能否进行荧光素眼底血管造影?

doi:10.24920/J1001-9294.2017.015

Abstract

Metformin is a kind of biguanide hypoglycemic agent that has been widely used in patients with diabetes mellitus. In clinical practice, whether metformin should be stopped before Fundus fluorescein angiography (FFA) remains largely unclear. Some endocrinologists suggest stop metformin before FFA. However, ophthalmologists do not always adopt this opinion in their practice. This situation may lead to disputes between physicians and patients. This article analyzed contrast-induced nephropathy(CIN) and the related contrast agent, as well as the adverse reactions of fluorescein angiography. It pointed out that the discrepancy may be caused by misunderstanding of contrast agents used in FFA. For angiography using iodine contrast agent, metformin must be stopped because of the increased possibility of CIN, while for FFA using fluorescein sodium, no CIN has been reported yet. Therefore, the authors believe FFA is safe for diabetic patients with oral metformin and it is unnecessary to stop metformin before the examination.

Key words: fundus fluorescein angiography, diabetes mellitus, metformin, contrast-induced nephropathy

Du Junhui, Li Rong. Can Fundus Fluorescein Angiography be Performed for Diabetic Patients on Oral Metformin?^△[J].Chinese Medical Sciences Journal, 2017, 32(2): 119-122.

Figures/Tables 1

References 25.

1.	Azzalini L, Spagnoli V, Ly H Q.Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol 2016;32:247-55. doi:10.1016/j.cjca.2015.05.013.
2.	Mruk B.Renal safety of iodinated contrast media depending on their osmolarity-current outlooks. Pol J Radiol 2016; 81:157-65. doi:10.12659/PJR.895406.
3.	Gruberg L, Mehran R, Dangas G, et al.Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001; 52: 409-16. doi:10.1002/ccd.1093.
4.	Moore RD, Steinberg EP, Powe NR, et al.Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992; 182:649-55. doi:10.1148/radiology.182.3.1535876.
5.	Heyman SN, Rosenberger C, Rosen S, et al.Why is diabetes mellitus a risk factor for contrast-induced nephropathy? Biomed Res Int 2013; 2013: 123589. doi:10. 1155/ 2013/123589.
6.	Mueller C, Buerkle G, Buettner HJ, et al.Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329-36. doi:10.1001/archinte.162.3.329.
7.	Assareh A, Yazdankhah S, Majidi S, et al.Contrast induced nephropathy among patients with normal renal function undergoing coronary angiography. J Renal Inj Prev 2016; 5: 21-4. doi:10.15171/jrip.2016.05.
8.	Soma V R, Cavusoglu E, Vidhun R, et al.Contrast-associated nephropathy. Heart Dis 2002; 4: 372-9. doi:10.1097/01.HDX.0000038530.32977.2F.
9.	Malik A.Prevention of contrast-induced acute kidney injury. Br J Hosp Med 2015; 76:685-9. doi:10.12968/ hmed.2015.76.12.685.
10.	Bruijstens LA, van Luin M, Buscher-Jungerhans PM, et al. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med 2008; 66:185-90.
11.	Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011; 21:2527-41. doi:10.1007/s00330-011-2225-0.
12.	Heng LZ, Comyn O, Peto T, et al.Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med 2013; 30: 640-50. doi:10. 1111/dme.12089.
13.	Zhang K, Wang Y, Chen XL. Fluorescein fundus angiography for early diagnosis of diabetic retinopathy significance. J Clin ophthalmol 2015; 23: 323-5. Chinese. doi:10.3969/j.issn.1006-8422.2015.04.012.
14.	Lv G, Tang LZ, Meng J. The significance of fundus fluorescein angiography after panretinal photocoagulation. Chin J Ocular trauma and occupational eye disease 2015; 37: 295-7. Chinese. doi:10.3760/cma.j.issn.2095-1477.2015.04.016.
15.	Jost G, Lengsfeld P, Lenhard DC, et al.Viscosity of iodinated contrast agents during renal excretion. Eur J Radiol 2011; 80: 373-7. doi:10.1016/j.ejrad.2011.02.003.
16.	Kwan AS, Barry C, McAllister IL, et al. Fluorescein angiography and adverse drug reactions revisited: the Lions Eye experience. Clin Experiment Ophthalmol. 2006; 34: 33-8. doi:10.1111/j.1442-9071.2006.01136.x.
17.	Karhunen U, Raitta C, Kala R.Adverse reactions to fluorescein angiography. Acta Ophthalmol (Copenh) 1986; 64:282-6.
18.	Butner RW, McPherson AR. Adverse reactions in intravenous fluorescein angiography. Ann Ophthalmol 1983; 15:1084-6.
19.	Kwiterovich KA, Maguire MG, Murphy RP, et al.Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology 1991; 98:1139-42.
20.	Lira RP, Oliveira CL, Marques MV, et al.Adverse reactions of fluorescein angiography: a prospective study. Arq Bras Oftalmol 2007; 70: 615-8.
21.	Ma H. Clinical observation on adverse reactions of fluorescence fundus angiography. Chin J ocular fundus disea. 2011; 27: 175-6. Chinese. doi:10.3760/cma.j.issn.1005-1015.2011.02.018.
22.	Liu J, Zhou J, Fang L. Fundus fluorescein angiography fluorescein sodium is used to analysis of 2620. Chin J Misdiagnosis 2008; 8: 8443. Chinese. doi:10.3969/j.issn.1009-6647.2008.34.120.
23.	Wei GC, Sun W. The adverse reactions of fluorescence fundus angiography and its countermeasures. Chin J Practical Ophthalmology 2006; 24: 636-7. Chinese. doi:10.3760/cma.j.issn.1006-4443.2006.06.030.
24.	Yannuzzi LA, Rohrer KT, Tindel LJ, et al.Fluorescein angiography complication survey. Ophthalmology 1986; 93: 611-7.
25.	Su ZA, Zhang LX, Teng Y. Special groups of the adverse reactions of fluorescence fundus angiography. Chin Med J 2009; 89: 1490-2. Chinese. doi:10.3760/cma.j.issn.0376-2491.2009.21.015.

Author of studies	Number of cases	Incidence in total (%)	Adverse reactions
Author of studies	Number of cases	Incidence in total (%)	Nausea or vomiting (%)	Itching or rash (%)	Dizziness or sweating (%)	Others^a (%)	Severe adverse reactions^b(%)
Kwan et al¹⁶	11898	1.1	1.1	0.2	0.3	0.2	0
Karhunen et al¹⁷	9909	7.26	5.9	0.5	0.6	0.26	0.03
Butner et al¹⁸	5000	4.82	4.02	0.34	-	-	0
Kwiterovich et al¹⁹	2789	4.8	4.1	0.5	-	0.2	0
Lira et al²⁰	1500	9.24	8.18	1.06	-	-	0.3
Ma H et al²¹	3565	2.50	1.18	0.67	-	0.56	0.8
Liu J et al²²	2620	0.34	0.07	0.07	0.07	0.11	0
Wei GC et al²³	1119	7.06	5.27	0.36	0.71	0.71	0

[1]	Kunrong Wu, Shufang Zhang, Ziwan Guan, Xiaoli Li, Rui Li, Ying Yin, Yan Li. Methylenetetrahydrofolate Reductase Gene Polymorphism C677T is Associated with Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients [J]. Chinese Medical Sciences Journal, 2021, 36(2): 103-109.
[2]	Honglin Zu,Likun Hou,Hongwei Liu,Yuanbo Zhan,Ju He. Identify Candidate Genes in the Interaction between Abdominal Aortic Aneurysm and Type 2 Diabetes Mellitus by Using Biomedical Discovery Support System [J]. Chinese Medical Sciences Journal, 2021, 36(1): 50-56.
[3]	Lin Ye, Wang Zhenlian, Yan Min, Zhu Feiyu, Duan Ye, Sun Zhiqin. Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials [J]. Chinese Medical Sciences Journal, 2020, 35(3): 226-238.
[4]	Yin Ying, Li Rui, Li Xiaoli, Wu Kunrong, Li Ling, Xu Yuedong, Liao Lin, Yang Rui, Li Yan. Association Between Homocysteine Level and Methylenetetrahydrofolate Reductase Gene Polymorphisms in Type 2 Diabetes Accompanied by Dyslipidemia [J]. Chinese Medical Sciences Journal, 2020, 35(1): 85-91.
[5]	Chen Qiang, Zhang Liwei, Huang Dangsheng, Zhang Chunhong, Wang Qiushuang, Shen Dong, Xiong Minjun, Yang Feifei. Five-year Clinical Outcomes of CAD Patients Complicated with Diabetes after StentBoost-optimized Percutaneous Coronary Intervention [J]. Chinese Medical Sciences Journal, 2019, 34(3): 177-183.
[6]	Chen Zhiye, Zang Xiujuan, Liu Mengqi, Liu Mengyu, Li Jinfeng, Gu Zhaoyan, Ma Lin. Abnormal Alterations of Cortical Thickness in 16 Patients with Type 2 Diabetes Mellitus: A Pilot MRI Study^△ [J]. Chinese Medical Sciences Journal, 2017, 32(2): 75-82.
[7]	Yang Yingying, Pan Hui, Wang Bo, Chen Shi, Zhu Huijuan. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials [J]. Chinese Medical Sciences Journal, 2017, 32(1): 22-27.
[8]	Jing Yang, Mei-cen Zhou, Kai Feng, Ou Wang, Hua-bing Zhang, Wei Li, Fan Ping, Jing Yang, Yu-xiu Li. Clinical Characteristics of 261 Cases of Hospitalized Patients with Type 1 Diabetes Mellitus [J]. Chinese Medical Sciences Journal, 2016, 31(2): 69-75.
[9]	Ying Fan, Shan-xiao Zhang, Meng Ren, Li-feng Hong, Xiao-ni Yan. Impact of 1, 25-(OH)₂D₃ on Left Ventricular Hypertrophy in Type 2 Diabetic Rats [J]. Chinese Medical Sciences Journal, 2015, 30(2): 114-120.
[10]	Yi-jun Zhou*,Ai Li, Yu-ling Song, Hui Zhou, Yan Li, Yin-si Tang. Role of Sclerostin in the Bone Loss of Postmenopausal Chinese Women with Type 2 Diabetes [J]. Chinese Medical Sciences Journal, 2013, 28(3): 135-139.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Can Fundus Fluorescein Angiography be Performed for Diabetic Patients on Oral Metformin?^△

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 25.

Related Articles 10

Metrics

Recommended 10